$ABUS let's talk royalties... Let's suppose Moderna plans to sell vaccine for $60/dose and it requires two doses. They plan on trying to have 1 billion doses available in 2021. Let's say ABUS can strike a 2 percent royalty deal... That's $2.4 billion in revenue. Now add in the Pfizer and biontech deal and assume they will do half that and the valuation proposition for Arbutus a big number. $4 billon in revenue with minimal expenses puts share price of cash only at $50 per share. Not saying that's a realistic target, but it's possible to see how they could get there by 2022.